The Landscape of HER-2 ADCs in the Era of DS8201
With DS8201 continuously dominating the field of HER-2 solid tumors such as breast cancer, gastric cancer, and lung cancer, the pressure on other HER2-ADCs is increasing day by day. Faced with a suddenly strong competitor, various HER2-ADC manufacturers have their own responses; some choose to join forces when they cannot compete, quickly following in the … Read more